Tandem Diabetes Care (Nasdaq: TNDM) has named its next president and CEO, as current chief John Sheridan plans to retire at the end of this year. Jeannette Bankes will lead the company starting Nov. 16. Most recently president and CEO of GE HealthCare’s patient care solutions business, Bankes has also served as a senior vice […]
Diabetes
MiniMed names new CMO ahead of planned retirement
MiniMed (Nasdaq: MMED) has named a new chief medical officer, as its current leader plans to retire at the end of next year. Dr. David Segal takes over for Dr. Robert Vigersky, who will now move into an emeritus position after holding the title of CMO since 2019 — back when the newly independent company […]
Insulet earnings trounce Q3 estimates as it narrows guidance
Insulet’s (Nasdaq: PODD) third quarter outpaced its own expectations and those of Wall Street, boosted by international sales of its Omnipod 5 tubeless insulin pump. Total revenue reached $842.0 million, for a 19.6% gain over the prior year, topping the company’s previous guidance and analysts’ estimates of $832.6 million. The U.S. haul accounted for $570.4 […]
Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
Dexcom (Nasdaq:DXCM) topped Wall Street’s expectations for third-quarter earnings, and the company nudged up its guidance for the remainder of the year as it looks ahead to a potential Medicare coverage decision that could expand the company’s reach in type 2 diabetes. Revenue reached $1.34 billion for an 11% gain over the prior year. U.S. […]
Sensonics launches human feasibility study for transmitter-free Eversense CGM
Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor. The first-in-human trial of its Freedom system will evaluate a one-year, under-the-skin sensor that links directly with the user’s smartphone, doing away with the need for additional on-body hardware and making a CGM as discreet […]
Abbott sets Libre Duo glucose-ketone sensor US launch for December
After claiming an FDA de novo nod in August, Abbott (NYSE: ABT) said it plans to launch its Libre Duo dual-analyte sensor in the U.S. this December. The roll out of the new continuous glucose monitor, which also tracks ketone levels to safeguard against diabetic ketoacidosis, will come after its international debut set for this […]
Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
Sequel Med Tech‘s twiist automated insulin delivery system obtained an FDA clearance opening up its use to adults with type 2 diabetes. Launched earlier this year for people with type 1 diabetes, the company estimates the agency’s green light adds about 5.5 million people in the U.S. who manage their condition with insulin. Available through […]
MiniMed completes split from Medtronic
MiniMed (Nasdaq: MMED) is celebrating its first day as an independent diabetes tech company, with the full completion of its spinoff from the Medtronic mothership. This week Medtronic reported the final results of its exchange offer for MiniMed stock, where it divested all of its remaining equity stake in the company through the swapping of […]
Insulet’s Omnipod Discover data platform begins full US rollout
Insulet’s (NASDAQ: PODD) web-based diabetes data platform is making its way to the U.S., designed to offer Omnipod users a view into their glucose and insulin trends while providing clinicians a way to deliver personalized recommendations. Dubbed Omnipod Discover, the system made its debut in multiple international markets earlier this year. Ahead of its full […]
Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
Novo (NYSE: NVO) has tapped the Swedish drug-delivery developer Nanexa to develop long-acting injectable platforms for its peptide meds, with a global licensing deal worth €1.165 billion, or about $1.32 billion U.S. The deal will support up to five R&D programs targeting monthly and quarterly injections, as the drugmaker looks to extend the reach of […]
